XXEC Inc. Invests $18.36 Million in Heartflow, Inc. $HTFL

XXEC Inc. bought a new position in shares of Heartflow, Inc. (NASDAQ:HTFL) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 599,194 shares of the company’s stock, valued at approximately $18,364,000. Heartflow accounts for about 0.0% of XXEC Inc.’s holdings, making the stock its 20th largest holding.

Other large investors have also recently bought and sold shares of the company. TrueMark Investments LLC boosted its holdings in shares of Heartflow by 1.4% during the first quarter. TrueMark Investments LLC now owns 26,885 shares of the company’s stock worth $654,000 after acquiring an additional 379 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Heartflow during the fourth quarter worth approximately $27,000. Strs Ohio lifted its holdings in Heartflow by 35.3% during the 1st quarter. Strs Ohio now owns 4,600 shares of the company’s stock worth $112,000 after purchasing an additional 1,200 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Heartflow during the 4th quarter worth approximately $45,000. Finally, Legal & General Group Plc bought a new stake in Heartflow in the 3rd quarter valued at $59,000.

Heartflow Price Performance

Shares of NASDAQ:HTFL opened at $48.10 on Friday. The business’s 50 day simple moving average is $31.97 and its 200 day simple moving average is $28.93. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $51.19. The company has a market capitalization of $4.18 billion and a P/E ratio of -26.28.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15. The firm had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The firm’s revenue was up 47.7% on a year-over-year basis. On average, sell-side analysts anticipate that Heartflow, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Piper Sandler reiterated an “overweight” rating and set a $45.00 price objective (up from $38.00) on shares of Heartflow in a research report on Friday, August 14th. Morgan Stanley boosted their target price on shares of Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. Wells Fargo & Company upped their price target on shares of Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Finally, Robert W. Baird set a $45.00 price objective on shares of Heartflow in a research note on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Heartflow has an average rating of “Moderate Buy” and a consensus price target of $43.43.

Insiders Place Their Bets

In other Heartflow news, CEO John C.M. Farquhar sold 38,900 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the sale, the chief executive officer directly owned 457,935 shares in the company, valued at $16,027,725. This represents a 7.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $41.23, for a total transaction of $380,099.37. Following the completion of the transaction, the insider directly owned 86,459 shares in the company, valued at approximately $3,564,704.57. This represents a 9.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 191,271 shares of company stock worth $7,089,136 in the last 90 days. 7.70% of the stock is owned by company insiders.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.